Portnoy Jay, Ciaccio Christina E, Beausoleil Janet, Du Toit George, Fineman Stanley, Tilles Stephen A, Zhang June, Lawrence Claire, Yassine Mohamed, Mustafa S Shahzad
Section of Allergy, Asthma & Immunology. Children's Mercy Hospital, Kansas City, MO, United States.
Section of Allergy/Immunology and Pediatric Pulmonology, The University of Chicago, Chicago, IL, United States.
Allergy Asthma Clin Immunol. 2022 May 9;18(1):37. doi: 10.1186/s13223-022-00671-5.
Shared learnings from the early use of novel therapies can aid in their optimization. The recent introduction of peanut oral immunotherapy (peanut OIT; Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp]) for peanut allergy addresses a significant unmet need but also highlights the requirement for consideration of several factors by both prescribers and patients.
To provide guidance for prescribers of licenced peanut OIT to facilitate treatment delivery and improve outcomes.
Clinicians with experience of licenced peanut OIT (United States n = 6, United Kingdom n = 1) participated in a series of interviews and group discussions designed to elicit tips for successful implementation.
Clinicians identified 8 tips that were considered the most relevant, practical, and impactful for prescribers of Peanut (Arachis hypogaea) Allergen Powder-dnfp: (1) preparing to provide treatment, (2) assessing the medical indication for treatment and (3) shared decision making, (4) staff education, (5) establishing office processes, (6) managing patient expectations and using anticipatory guidance, (7) optimising adherence and (8) maintaining flexibility throughout the treatment process. In addition, a range of supporting materials (e.g., checklists and action plans) are provided.
The introduction of a novel therapy often requires healthcare providers to modify or adopt practices to effectively employ the treatment. The provision of guidance based upon early real-world experiences of licenced peanut OIT may help inform clinical practice and improve treatment outcomes.
从新型疗法的早期应用中获得的共同经验有助于对其进行优化。最近引入的用于花生过敏的花生口服免疫疗法（花生OIT；Palforzia[花生（落花生）变应原粉末-dnfp]）满足了一项重大的未满足需求，但也凸显了开处方者和患者都需要考虑多个因素。
为获得许可的花生OIT的开处方者提供指导，以促进治疗实施并改善治疗效果。
有获得许可的花生OIT使用经验的临床医生（美国n = 6，英国n = 1）参与了一系列访谈和小组讨论，旨在获取成功实施的技巧。
临床医生确定了8条被认为对花生（落花生）变应原粉末-dnfp的开处方者最相关、实用且有影响力的技巧：（1）准备提供治疗，（2）评估治疗的医学指征，（3）共同决策，（4）员工教育，（5）建立办公室流程，（6）管理患者期望并使用预期指导，（7）优化依从性，（8）在整个治疗过程中保持灵活性。此外，还提供了一系列辅助材料（如检查表和行动计划）。
新型疗法的引入通常要求医疗保健提供者修改或采用相关做法以有效应用该治疗。基于获得许可的花生OIT的早期实际经验提供指导可能有助于为临床实践提供参考并改善治疗效果。
